{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:28:18Z","timestamp":1770481698922,"version":"3.49.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,2,24]],"date-time":"2008-02-24T00:00:00Z","timestamp":1203811200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1007\/s00213-008-1098-7","type":"journal-article","created":{"date-parts":[[2008,2,23]],"date-time":"2008-02-23T19:03:19Z","timestamp":1203793399000},"page":"103-111","source":"Crossref","is-referenced-by-count":33,"title":["Differential regional and dose-related effects of asenapine on dopamine receptor subtypes"],"prefix":"10.1007","volume":"198","author":[{"given":"Frank I.","family":"Tarazi","sequence":"first","affiliation":[]},{"given":"Taylor","family":"Moran-Gates","sequence":"additional","affiliation":[]},{"given":"Erik H. F.","family":"Wong","sequence":"additional","affiliation":[]},{"given":"Brian","family":"Henry","sequence":"additional","affiliation":[]},{"given":"Mohammed","family":"Shahid","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2008,2,24]]},"reference":[{"key":"1098_CR1","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1176\/ajp.155.11.1550","volume":"155","author":"A Abi-Dargham","year":"1998","unstructured":"Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761\u2013767","journal-title":"Am J Psychiatry"},{"key":"1098_CR2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1081\/RRS-200029953","volume":"24","author":"JA Ahlgren-Beckendorf","year":"2004","unstructured":"Ahlgren-Beckendorf JA, Levant B (2004) Signaling mechanisms of the D3 dopamine receptor. J Recept Signal Transduct Res 24:117\u2013130","journal-title":"J Recept Signal Transduct Res"},{"key":"1098_CR3","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/0166-2236(89)90074-X","volume":"12","author":"RL Albin","year":"1989","unstructured":"Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366\u2013375","journal-title":"Trends Neurosci"},{"key":"1098_CR4","first-page":"95","volume":"2","author":"BM Angrist","year":"1970","unstructured":"Angrist BM, Gershon S (1970) The phenomenology of experimentally induced amphetamine psychosis\u2013preliminary observations. Biol Psychiatry 2:95\u2013107","journal-title":"Biol Psychiatry"},{"key":"1098_CR5","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1056\/NEJM197711032971807","volume":"297","author":"RJ Baldessarini","year":"1977","unstructured":"Baldessarini RJ (1977) Schizophrenia. N Engl J Med 297:988\u2013995","journal-title":"N Engl J Med"},{"key":"1098_CR6","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1056\/NEJM199103143241107","volume":"324","author":"RJ Baldessarini","year":"1991","unstructured":"Baldessarini RJ, Frankenburg FR (1991) Clozapine. A novel antipsychotic agent. N Engl J Med 324:746\u2013754","journal-title":"N Engl J Med"},{"key":"1098_CR7","first-page":"461","volume-title":"Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics","author":"RJ Baldessarini","year":"2005","unstructured":"Baldessarini RJ, Tarazi FI (2005) Pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, pp 461\u2013500"},{"key":"1098_CR8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/syn.10253","volume":"50","author":"C Bishop","year":"2003","unstructured":"Bishop C, Kamdar DP, Walker PD (2003) Intrastriatal serotonin 5-HT2 receptors mediate dopamine D1-induced hyperlocomotion in 6-hydroxydopamine-lesioned rats. Synapse 50:164\u2013170","journal-title":"Synapse"},{"key":"1098_CR9","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.neuropharm.2005.03.008","volume":"49","author":"C Bishop","year":"2005","unstructured":"Bishop C, Daut GS, Walker PD (2005) Serotonin 5-HT2A but not 5-HT2C receptor antagonism reduces hyperlocomotor activity induced in dopamine-depleted rats by striatal administration of the D1 agonist SKF 82958. Neuropharmacology 49:350\u2013358","journal-title":"Neuropharmacology"},{"key":"1098_CR10","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1073\/pnas.94.6.2569","volume":"94","author":"A Breier","year":"1997","unstructured":"Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94:2569\u20132574","journal-title":"Proc Natl Acad Sci USA"},{"key":"1098_CR11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0893-133X(95)00068-O","volume":"13","author":"N Brunello","year":"1995","unstructured":"Brunello N, Masotto C, Steardo L, Markstein R, Racagni G (1995) New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13:177\u2013213","journal-title":"Neuropsychopharmacology"},{"key":"1098_CR12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","volume":"14","author":"FP Bymaster","year":"1996","unstructured":"Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87\u201396","journal-title":"Neuropsychopharmacology"},{"key":"1098_CR13","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.biopsych.2003.10.004","volume":"55","author":"MH Corrigan","year":"2004","unstructured":"Corrigan MH, Gallen CC, Bonura ML, Merchant KM (2004) Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial. Biol Psychiatry 55:445\u2013451","journal-title":"Biol Psychiatry"},{"key":"1098_CR14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","volume":"192","author":"I Creese","year":"1976","unstructured":"Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481\u2013483","journal-title":"Science"},{"key":"1098_CR15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0169-328X(96)00101-5","volume":"41","author":"SP Damask","year":"1996","unstructured":"Damask SP, Bovenkerk KA, de la Pena G, Hoversten KM, Peters DB, Valentine AM, Meador-Woodruff JH (1996) Differential effects of clozapine and haloperidol on dopamine receptor mRNA expression in rat striatum and cortex. Brain Res Mol Brain Res 41:241\u2013249","journal-title":"Brain Res Mol Brain Res"},{"key":"1098_CR16","doi-asserted-by":"crossref","unstructured":"Fleming K, Potkin SG, Binneman B, Keller DS, Alphs L, Panagides J (2007) Asenapine improves cognitive function in acute schizophrenia: a placebo- and risperidone-controlled trial. Paper presented at: 160th Annual Meeting of the American Psychiatric Association. San Diego, CA, USA","DOI":"10.1016\/S0924-977X(07)70710-1"},{"key":"1098_CR17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0022-3565(24)36475-4","volume":"280","author":"WJ Florijn","year":"1997","unstructured":"Florijn WJ, Tarazi FI, Creese I (1997) Dopamine receptor subtypes: differential regulation after 8\u00a0months treatment with antipsychotic drugs. J Pharmacol Exp Ther 280:561\u2013569","journal-title":"J Pharmacol Exp Ther"},{"key":"1098_CR18","doi-asserted-by":"crossref","unstructured":"Fr\u00e5nberg O, Wiker C, Marcus MM, Konradsson A, Jardemark K, Schilstr\u00f6m B, Shahid M, Wong EH, Svensson TH (2008) Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (in press)","DOI":"10.1007\/s00213-007-0973-y"},{"key":"1098_CR19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1385\/JMN:22:3:167","volume":"22","author":"L Gan","year":"2004","unstructured":"Gan L, Falzone TL, Zhang K, Rubinstein M, Baldessarini RJ, Tarazi FI (2004) Enhanced expression of dopamine D1 and glutamate NMDA receptors in dopamine D4 receptor knockout mice. J Mol Neurosci 22:167\u2013178","journal-title":"J Mol Neurosci"},{"key":"1098_CR20","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1038\/sj.npp.1300975","volume":"31","author":"XM Gao","year":"2006","unstructured":"Gao XM, Cooper T, Suckow RF, Tamminga CA (2006) Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia. Neuropsychopharmacology 31:1864\u20131868","journal-title":"Neuropsychopharmacology"},{"key":"1098_CR21","first-page":"3","volume":"174","author":"PS Goldman-Rakic","year":"2004","unstructured":"Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV (2004) Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 174:3\u201316","journal-title":"Psychopharmacology (Berl)"},{"key":"1098_CR22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/hipo.450040318","volume":"4","author":"SK Goldsmith","year":"1994","unstructured":"Goldsmith SK, Joyce JN (1994) Dopamine D2 receptor expression in hippocampus and parahippocampal cortex of rat, cat, and human in relation to tyrosine hydroxylase-immunoreactive fibers. Hippocampus 4:354\u2013373","journal-title":"Hippocampus"},{"key":"1098_CR23","first-page":"462","volume-title":"Econometric analysis","author":"WH Greene","year":"2000","unstructured":"Greene WH (2000) Econometric analysis, 4th edn. Prentice Hall, Upper Saddle River, pp 462\u2013465","edition":"4"},{"key":"1098_CR24","first-page":"325","volume-title":"Neuropsychiatry","author":"DV Jeste","year":"1996","unstructured":"Jeste DV, Galasko D, Corey-Bloom J, Walens S, Granholm E (1996) Neuropsychiatric aspects of the schizophrenias. In: Fogel BS, Schiffer RB, Rao SM (eds) Neuropsychiatry. Williams and Wilkins, Balitimore, pp 325\u2013344"},{"key":"1098_CR25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0022-3956(97)00018-6","volume":"32","author":"DV Jeste","year":"1998","unstructured":"Jeste DV, Lohr JB, Eastham JH, Rockwell E, Caligiuri MP (1998) Adverse neurobiological effects of long-term use of neuroleptics: human and animal studies. J Psychiatr Res 32:201\u2013214","journal-title":"J Psychiatr Res"},{"key":"1098_CR26","first-page":"1188","volume-title":"Principles of Neural Science","author":"ER Kandel","year":"2000","unstructured":"Kandel ER (2000) Disorders of thought and volition: schizophrenia. In: Kandel ER, Schwartz JH, Jessell TM (eds) Principles of Neural Science. Elsevier, New York, pp 1188\u20131208"},{"key":"1098_CR27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.nurx.2005.12.003","volume":"3","author":"S Kapur","year":"2006","unstructured":"Kapur S, Agid O, Mizrahi R, Li M (2006) How antipsychotics work-from receptors to reality. NeuroRx. 3:10\u201321","journal-title":"NeuroRx."},{"key":"1098_CR28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1001\/archpsyc.1997.01830180085011","volume":"54","author":"MS Kramer","year":"1997","unstructured":"Kramer MS, Last B, Getson A, Reines SA (1997) The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. Arch Gen Psychiatry 54:567\u2013572","journal-title":"Arch Gen Psychiatry"},{"key":"1098_CR29","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/0006-3223(92)90242-R","volume":"31","author":"EE Krieckhaus","year":"1992","unstructured":"Krieckhaus EE, Donahoe JW, Morgan MA (1992) Paranoid schizophrenia may be caused by dopamine hyperactivity of CA1 hippocampus. Biol Psychiatry 31:560\u2013570","journal-title":"Biol Psychiatry"},{"key":"1098_CR30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0893-133X(95)00049-J","volume":"13","author":"M Kuoppamaki","year":"1995","unstructured":"Kuoppamaki M, Palvimaki EP, Hietala J, Syvalahti E (1995) Differential regulation of rat 5-HT2A and 5-HT2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs. Neuropsychopharmacology 13:139\u2013150","journal-title":"Neuropsychopharmacology"},{"key":"1098_CR31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s007020050024","volume":"107","author":"I Kusumi","year":"2000","unstructured":"Kusumi I, Takahashi Y, Suzuki K, Kameda K, Koyama T (2000) Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. J Neural Transm 107:295\u2013302","journal-title":"J Neural Transm"},{"key":"1098_CR32","doi-asserted-by":"crossref","first-page":"9235","DOI":"10.1073\/pnas.93.17.9235","volume":"93","author":"M Laruelle","year":"1996","unstructured":"Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D\u2019Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93:9235\u20139240","journal-title":"Proc Natl Acad Sci USA"},{"key":"1098_CR33","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1073\/pnas.92.5.1719","volume":"92","author":"D Levesque","year":"1995","unstructured":"Levesque D, Martres MP, Diaz J, Griffon N, Lammers CH, Sokoloff P, Schwartz JC (1995) A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc Natl Acad Sci USA 92:1719\u20131723","journal-title":"Proc Natl Acad Sci USA"},{"key":"1098_CR34","first-page":"S138","volume":"30","author":"Z Li","year":"2005","unstructured":"Li Z, Shahid M, Meltzer HY (2005) Asenapine preferentially increases dopamine and acetylcholine efflux in rat medial prefrontal cortex and hippocampus [abstract]. Neuropsychopharmacology 30:S138","journal-title":"Neuropsychopharmacology"},{"key":"1098_CR35","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0022-3565(24)37099-5","volume":"283","author":"MS Lidow","year":"1997","unstructured":"Lidow MS, Goldman-Rakic PS (1997) Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs. J Pharmacol Exp Ther 283:939\u2013946","journal-title":"J Pharmacol Exp Ther"},{"key":"1098_CR36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF00216006","volume":"91","author":"JA Lieberman","year":"1987","unstructured":"Lieberman JA, Kane JM, Alvir J (1987) Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 91:415\u2013433","journal-title":"Psychopharmacology (Berl)"},{"key":"1098_CR37","doi-asserted-by":"crossref","first-page":"11424","DOI":"10.1523\/JNEUROSCI.2847-07.2007","volume":"27","author":"DJ Lodge","year":"2007","unstructured":"Lodge DJ, Grace AA (2007) Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J Neurosci 27:11424\u201311430","journal-title":"J Neurosci"},{"key":"1098_CR38","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0091-3057(93)90104-2","volume":"45","author":"C Marin","year":"1993","unstructured":"Marin C, Parashos SA, Kapitzoglou-Logothetis V, Peppe A, Chase TN (1993) D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity. Pharmacol Biochem Behav 45:195\u2013200","journal-title":"Pharmacol Biochem Behav"},{"issue":"Suppl","key":"1098_CR39","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1007\/BF00442554","volume":"99","author":"HY Meltzer","year":"1989","unstructured":"Meltzer HY (1989) Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 99(Suppl):S18\u2013S27","journal-title":"Psychopharmacology (Berl)"},{"key":"1098_CR40","first-page":"238","volume":"251","author":"HY Meltzer","year":"1989","unstructured":"Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238\u2013246","journal-title":"J Pharmacol Exp Ther"},{"key":"1098_CR41","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/syn.20220","volume":"59","author":"T Moran-Gates","year":"2006","unstructured":"Moran-Gates T, Gan L, Park YS, Zhang K, Baldessarini RJ, Tarazi FI (2006) Repeated antipsychotic drug exposure in developing rats: dopamine receptor effects. Synapse 59:92\u2013100","journal-title":"Synapse"},{"key":"1098_CR42","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/BF02244112","volume":"102","author":"SA Parashos","year":"1990","unstructured":"Parashos SA, Marin C, Barone P, Kapitzoglou-Logothetis V, Chase TN (1990) Effect of chronic D1 and\/or D2 dopamine antagonist treatment on SKF 38393-induced non-stereotyped grooming. Psychopharmacology (Berl) 102:411\u2013413","journal-title":"Psychopharmacology (Berl)"},{"key":"1098_CR43","volume-title":"The rat brain in stereotaxic coordinates","author":"G Paxinos","year":"1982","unstructured":"Paxinos G, Watson C (1982) The rat brain in stereotaxic coordinates. Academic, London"},{"key":"1098_CR44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","volume":"124","author":"A Schotte","year":"1996","unstructured":"Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124:57\u201373","journal-title":"Psychopharmacology (Berl)"},{"key":"1098_CR45","doi-asserted-by":"crossref","unstructured":"Shahid M, Walker GB, Zorn SH, Wong EHF (2008) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. Journal of Psychopharmacology (in press)","DOI":"10.1177\/0269881107082944"},{"key":"1098_CR46","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/1029842021000045499","volume":"4","author":"P Sokoloff","year":"2002","unstructured":"Sokoloff P, Guillin O, Diaz J, Carroll P, Griffon N (2002) Brain-derived neurotrophic factor controls dopamine D3 receptor expression: implications for neurodevelopmental psychiatric disorders. Neurotox Res 4:671\u2013678","journal-title":"Neurotox Res"},{"key":"1098_CR47","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/350614a0","volume":"350","author":"RK Sunahara","year":"1991","unstructured":"Sunahara RK, Guan HC, O\u2019Dowd BF, Seeman P, Laurier LG, Ng G, George SR, Torchia J, Van Tol HH, Niznik HB (1991) Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 350:614\u2013619","journal-title":"Nature"},{"issue":"Suppl 9","key":"1098_CR48","first-page":"9","volume":"67","author":"CA Tamminga","year":"2006","unstructured":"Tamminga CA (2006) The neurobiology of cognition in schizophrenia. J Clin Psychiatry 67(Suppl 9):9\u201313","journal-title":"J Clin Psychiatry"},{"key":"1098_CR49","first-page":"495","volume":"268","author":"L Tang","year":"1994","unstructured":"Tang L, Todd RD, Heller A, O\u2019Malley KL (1994) Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines. J Pharmacol Exp Ther 268:495\u2013502","journal-title":"J Pharmacol Exp Ther"},{"key":"1098_CR50","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1097\/00001756-199711100-00001","volume":"8","author":"FI Tarazi","year":"1997","unstructured":"Tarazi FI, Kula NS, Baldessarini RJ (1997a) Regional distribution of dopamine D4 receptors in rat forebrain. Neuroreport 8:3423\u20133426","journal-title":"Neuroreport"},{"key":"1098_CR51","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0893-133X(97)00046-8","volume":"17","author":"FI Tarazi","year":"1997","unstructured":"Tarazi FI, Yeghiayan SK, Baldessarini RJ, Kula NS, Neumeyer JL (1997b) Long-term effects of S(+)N-n-propylnorapomorphine compared with typical and atypical antipsychotics: differential increases of cerebrocortical D2-like and striatolimbic D4-like dopamine receptors. Neuropsychopharmacology 17:186\u2013196","journal-title":"Neuropsychopharmacology"},{"key":"1098_CR52","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0278-5846(98)00033-5","volume":"22","author":"FI Tarazi","year":"1998","unstructured":"Tarazi FI, Yeghiayan SK, Neumeyer JL, Baldessarini RJ (1998) Medial prefrontal cortical D2 and striatolimbic D4 dopamine receptors: common targets for typical and atypical antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry 22:693\u2013707","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1098_CR53","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0022-3565(24)29589-6","volume":"297","author":"FI Tarazi","year":"2001","unstructured":"Tarazi FI, Zhang K, Baldessarini RJ (2001) Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 297:711\u2013717","journal-title":"J Pharmacol Exp Ther"},{"key":"1098_CR54","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00213-002-1016-3","volume":"161","author":"FI Tarazi","year":"2002","unstructured":"Tarazi FI, Zhang K, Baldessarini RJ (2002) Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berl) 161:263\u2013270","journal-title":"Psychopharmacology (Berl)"},{"key":"1098_CR55","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00023210-200216010-00003","volume":"16","author":"D Tarsy","year":"2002","unstructured":"Tarsy D, Baldessarini RJ, Tarazi FI (2002) Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16:23\u201345","journal-title":"CNS Drugs"},{"key":"1098_CR56","first-page":"1","volume-title":"Schizophrenia and Mood Disorders","author":"JL Waddington","year":"2000","unstructured":"Waddington JL, Casey DE (2000) Comparative pharmacology of classical and novel (second-generation) antipsychotics. In: Waddington JL, Buckley PF (eds) Schizophrenia and Mood Disorders. Butterworth-Heinemann, Oxford, pp 1\u201313"},{"key":"1098_CR57","first-page":"165","volume-title":"Statistical principles in experimental drug design, third edition","author":"BJ Winer","year":"1991","unstructured":"Winer BJ, Brown DR, Michels KM (1991) Statistical principles in experimental drug design, third edition. McGraw Hill, New York, pp 165\u2013166"},{"key":"1098_CR58","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0006-8993(99)02024-7","volume":"847","author":"K Zhang","year":"1999","unstructured":"Zhang K, Weiss NT, Tarazi FI, Kula NS, Baldessarini RJ (1999) Effects of alkylating agents on dopamine D3 receptors: Selective protection by dopamine. Brain Res 847:32\u201337","journal-title":"Brain Res"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-008-1098-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-008-1098-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-008-1098-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T18:27:34Z","timestamp":1738088854000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-008-1098-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,24]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["1098"],"URL":"https:\/\/doi.org\/10.1007\/s00213-008-1098-7","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,24]]}}}